Welcome to our dedicated page for Verve Therapeutics SEC filings (Ticker: VERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Verve Therapeutics鈥� gene-editing disclosures can feel like wading through a lab notebook written in legalese. Risk factors span emerging CRISPR regulations, manufacturing hurdles and multi-million-dollar collaboration terms鈥攄etails scattered across 300-page 10-Ks and frequent 8-Ks after clinical readouts. If you have ever asked, 鈥淲here can I find Verve Therapeutics鈥� quarterly earnings report 10-Q filing?鈥� or needed Verve Therapeutics insider trading Form 4 transactions before a pivotal PCSK9 data drop, this page ends the search.
Stock Titan鈥檚 platform pairs every VERV submission鈥�10-K, 10-Q, 8-K, DEF 14A, S-1 and more鈥攚ith AI-powered summaries that explain trial milestones, cash runway shifts and licensing economics in plain English. Our engine flags Verve Therapeutics Form 4 insider transactions real-time, highlights executive stock awards in the proxy statement, and answers natural questions like 鈥淲hat does Verve report about ANGPTL3 safety?鈥� With instant alerts, you see each filing the moment it hits EDGAR, then skim concise AI notes instead of scrolling hundreds of footnotes.
Use this hub to: monitor management鈥檚 conviction through insider buys, compare R&D spending across quarters, track 8-K material events explained such as FDA clearances, and read a Verve Therapeutics annual report 10-K simplified section that links pipeline timelines to financial forecasts. Whether you鈥檙e studying understanding Verve Therapeutics SEC documents with AI for diligence or checking a Verve Therapeutics proxy statement executive compensation discussion, our coverage delivers every detail investors need鈥攏o biotech PhD required.
Celcuity Inc. (CELC) filed a Form 424B5 to raise $75 million through a common-stock offering, with a 30-day $11.25 million over-allotment option. The shares will list on Nasdaq; the last closing price (25-Jul-25) was $13.77. A concurrent but independent public issue of $150 million (up to $172.5 million) 2031 convertible senior notes is planned; proceeds will partly fund capped-call hedges designed to limit dilution from note conversion.
Clinical catalyst: On 28-Jul-25 positive topline Phase 3 data (VIKTORIA-1, PIK3CA wild-type cohort) showed gedatolisib triplet cut risk of progression or death by 76% vs. fulvestrant (HR 0.24; mPFS 9.3 mo vs 2.0 mo). The doublet cut risk by 67% (HR 0.33; mPFS 7.4 mo). Tolerability was better than prior studies. An NDA filing is targeted for 4Q-25; mutation-cohort data expected year-end 2025.
Balance-sheet moves: Cash, equivalents and short-term investments are estimated at $168.4 million as of 30-Jun-25 (vs $283.1 million YoY). Amendment to Innovatus/Oxford debt facility extends conversion right to May-26 and unlocks a $30 million Term D draw, which the company intends to access by 31-Aug-25. Combined cash, warrant exercises, Term D/E loans, and the two offerings are projected to fund operations into 2027, including both Phase 3 trials and potential commercial launch.
Key investor considerations: Offering proceeds (net not yet finalized) will cover capped-call costs and general corporate purposes, causing immediate dilution; future dilution may arise from options, warrants, preferred shares and potential note conversions. Risk factors highlight market-price volatility, financing needs, and execution of the notes offering.
On 07/24/2025, New York Times Company (NYSE: NYT) director Beth A. Brooke acquired 65 Class A shares in the form of dividend-equivalent restricted stock units (RSUs) granted under the 2020 Incentive Compensation Plan. The RSUs were issued at $0 cost, lifting her direct stake to 19,661 shares. Dividend-equivalent RSUs tied to already-vested awards are immediately vested; those related to unvested awards will vest at the company鈥檚 next annual meeting. No dispositions, options or derivative securities were reported. This appears to be a routine compensation event and is immaterial to the company鈥檚 capital structure.
- Transaction code: A (acquisition)
- Form filed by one reporting person
- Relationship: Director
Key take-aways from Verve Therapeutics (VERV) Form 4
On 25 Jul 2025, CFO Allison Dorval reported the disposition of all remaining Verve equity as a result of Eli Lilly鈥檚 previously announced acquisition. Transactions coded 鈥淯鈥� confirm automatic treatment under the 16 Jun 2025 merger agreement:
- 13,280 common shares tendered for $10.50 cash plus one CVR per share; post-transaction share balance: 0.
- Cash-out of 513,000 stock options (exercise prices $6.01鈥�$12.75) and 80,625 RSUs; all derivative positions now zero.
The filing notes the conversion mechanics: cash equal to the spread (where applicable) and issuance of a non-tradable CVR worth up to $3.00, contingent on a milestone. Completion of the tender offer and subsequent merger on 25 Jul 2025 leaves Verve as a wholly owned Lilly subsidiary; the reporting person is no longer a VERV insider.
Key take-aways from Verve Therapeutics (VERV) Form 4
On 25 Jul 2025, CFO Allison Dorval reported the disposition of all remaining Verve equity as a result of Eli Lilly鈥檚 previously announced acquisition. Transactions coded 鈥淯鈥� confirm automatic treatment under the 16 Jun 2025 merger agreement:
- 13,280 common shares tendered for $10.50 cash plus one CVR per share; post-transaction share balance: 0.
- Cash-out of 513,000 stock options (exercise prices $6.01鈥�$12.75) and 80,625 RSUs; all derivative positions now zero.
The filing notes the conversion mechanics: cash equal to the spread (where applicable) and issuance of a non-tradable CVR worth up to $3.00, contingent on a milestone. Completion of the tender offer and subsequent merger on 25 Jul 2025 leaves Verve as a wholly owned Lilly subsidiary; the reporting person is no longer a VERV insider.
Key take-aways from Verve Therapeutics (VERV) Form 4
On 25 Jul 2025, CFO Allison Dorval reported the disposition of all remaining Verve equity as a result of Eli Lilly鈥檚 previously announced acquisition. Transactions coded 鈥淯鈥� confirm automatic treatment under the 16 Jun 2025 merger agreement:
- 13,280 common shares tendered for $10.50 cash plus one CVR per share; post-transaction share balance: 0.
- Cash-out of 513,000 stock options (exercise prices $6.01鈥�$12.75) and 80,625 RSUs; all derivative positions now zero.
The filing notes the conversion mechanics: cash equal to the spread (where applicable) and issuance of a non-tradable CVR worth up to $3.00, contingent on a milestone. Completion of the tender offer and subsequent merger on 25 Jul 2025 leaves Verve as a wholly owned Lilly subsidiary; the reporting person is no longer a VERV insider.
Key take-aways from Verve Therapeutics (VERV) Form 4
On 25 Jul 2025, CFO Allison Dorval reported the disposition of all remaining Verve equity as a result of Eli Lilly鈥檚 previously announced acquisition. Transactions coded 鈥淯鈥� confirm automatic treatment under the 16 Jun 2025 merger agreement:
- 13,280 common shares tendered for $10.50 cash plus one CVR per share; post-transaction share balance: 0.
- Cash-out of 513,000 stock options (exercise prices $6.01鈥�$12.75) and 80,625 RSUs; all derivative positions now zero.
The filing notes the conversion mechanics: cash equal to the spread (where applicable) and issuance of a non-tradable CVR worth up to $3.00, contingent on a milestone. Completion of the tender offer and subsequent merger on 25 Jul 2025 leaves Verve as a wholly owned Lilly subsidiary; the reporting person is no longer a VERV insider.
Key take-aways from Verve Therapeutics (VERV) Form 4
On 25 Jul 2025, CFO Allison Dorval reported the disposition of all remaining Verve equity as a result of Eli Lilly鈥檚 previously announced acquisition. Transactions coded 鈥淯鈥� confirm automatic treatment under the 16 Jun 2025 merger agreement:
- 13,280 common shares tendered for $10.50 cash plus one CVR per share; post-transaction share balance: 0.
- Cash-out of 513,000 stock options (exercise prices $6.01鈥�$12.75) and 80,625 RSUs; all derivative positions now zero.
The filing notes the conversion mechanics: cash equal to the spread (where applicable) and issuance of a non-tradable CVR worth up to $3.00, contingent on a milestone. Completion of the tender offer and subsequent merger on 25 Jul 2025 leaves Verve as a wholly owned Lilly subsidiary; the reporting person is no longer a VERV insider.
Key take-aways from Verve Therapeutics (VERV) Form 4
On 25 Jul 2025, CFO Allison Dorval reported the disposition of all remaining Verve equity as a result of Eli Lilly鈥檚 previously announced acquisition. Transactions coded 鈥淯鈥� confirm automatic treatment under the 16 Jun 2025 merger agreement:
- 13,280 common shares tendered for $10.50 cash plus one CVR per share; post-transaction share balance: 0.
- Cash-out of 513,000 stock options (exercise prices $6.01鈥�$12.75) and 80,625 RSUs; all derivative positions now zero.
The filing notes the conversion mechanics: cash equal to the spread (where applicable) and issuance of a non-tradable CVR worth up to $3.00, contingent on a milestone. Completion of the tender offer and subsequent merger on 25 Jul 2025 leaves Verve as a wholly owned Lilly subsidiary; the reporting person is no longer a VERV insider.
Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:
- Elect six directors (current slate; five qualify as independent).
- Reprice 314,633 underwater stock options (鈮�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04鈥�125 % of the 10-day VWAP鈥攊f holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
- Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
- Authorize an adjournment if additional proxies are needed.
Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.
Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:
- Elect six directors (current slate; five qualify as independent).
- Reprice 314,633 underwater stock options (鈮�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04鈥�125 % of the 10-day VWAP鈥攊f holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
- Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
- Authorize an adjournment if additional proxies are needed.
Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
What is the primary focus of Verve Therapeutics?
Which genes are targeted by Verve Therapeutics' treatments?
How does Verve's approach differ from traditional cardiovascular treatments?
What clinical trials are currently underway at Verve Therapeutics?
What innovative technologies does Verve utilize in its therapies?
Who can benefit from Verve Therapeutics' treatments?
How does the company ensure safety in its gene editing therapies?
What distinguishes Verve Therapeutics in the biotechnology sector?
